Lv3
260 积分 2025-12-09 加入
Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling
2个月前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
2个月前
已完结
TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy
2个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
3个月前
已完结
Dual-Functional Anti-SIRPα-cGAMP Conjugate Reprograms the Tumor Immune Microenvironment and Enhances Antitumor Immunity
4个月前
已完结
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
4个月前
已完结
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
4个月前
已完结
Eosinophils as Major Player in Type 2 Inflammation: Autoimmunity and Beyond
5个月前
已完结
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas
6个月前
已完结
A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
6个月前
已完结
皖公网安备34019202002308
